Alteogen shares plunged up to 23.94% over U.S. drug price negotiation rules, but analysts point out that actual losses remain unconfirmed and Keytruda SC sales continue to grow.
Alteogen Plummets on U.S. Drug Pricing Regulations: Overreaction or Real Risk?
Alteogen shares plunged up to 23.94% over U.S. drug price negotiation rules, but analysts point out that actual losses remain unconfirmed and Keytruda SC sales continue to grow.
-5-800x600.webp)
MTIMES Global Editorial Statement
This analysis is provided for international business intelligence and informational purposes only. It does not constitute investment advice or a solicitation to buy or sell securities. For inquiries regarding licensing or syndication, please contact [email protected].
